Skip to main content

Table 1 Patient and tumor characteristics (n = 100)

From: Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung—prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT

Age, years, median 68 (43 – 88)
Sex: m/f, n 67 / 33
Weight loss > 5%/3 month, n (%) 29 (29)
Karnofsky Index, n (%)
  100 14 (14)
  90 26 (26)
  80 37 (37)
  70 12 (12)
  60 9 (9)
  50 2 (2)
COPD as comorbidity, n (%)
  Grade 2 34 (34)
    3 17 (17)
    4 2 (2)
Stage–grouping (UICC/ AJCC 8th edition), n (%)
  II A 2 (2)
  II B 10(10)
  III A 27 (27)
  III B 43 (43)
  III C 14 (14)
  IV A* 4 (4)
Histology/cytology, n (%)
  Adenocarcinoma 45 (45)
  Squamous cell carcinoma 51 (51)
  NSC—n. o. s 4 (4)
Tumor localisation, n (%)
  Central 37 (37)
  Peripheral 60 (60)
  Primary not detectable 3 (3)
Gross tumor volume, ccm, median (range)
  Group 1 (n = 17) 18 (4 – 47)
  Group 2 (n = 52) 45 (12 – 218)
  Group 3 (n = 20) 104 (46 – 255)
  Group 4 (n = 8) 241 (189 – 387)
  1. *Patients with separate tumor nodule(s) in a contralateral lobe (M1a)
  2. COPD = Chronic obstructive pulmonary disease, UICC = Union for international cancer control, AJCC = American Joint Commission on Cancer; FDG-PET = 18-fluorodeoxyglucose-positron emission tomography; NSC—n.o.s. = Non-small cell—not otherwise specified